Protara Therapeutics, Inc. (NASDAQ:TARA) Receives $20.40 Consensus Target Price from Analysts

Protara Therapeutics, Inc. (NASDAQ:TARA) has been assigned an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $20.40.

A number of equities research analysts have recently issued reports on TARA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Protara Therapeutics in a report on Thursday, January 22nd. Piper Sandler assumed coverage on shares of Protara Therapeutics in a research note on Wednesday, January 7th. They set an “overweight” rating and a $24.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $23.00 target price on shares of Protara Therapeutics in a report on Tuesday, February 10th.

Protara Therapeutics Stock Down 0.3%

Shares of NASDAQ TARA opened at $6.51 on Tuesday. Protara Therapeutics has a 12 month low of $2.77 and a 12 month high of $7.82. The company has a market cap of $336.12 million, a price-to-earnings ratio of -4.55 and a beta of 1.38. The business has a fifty day simple moving average of $5.84 and a 200-day simple moving average of $4.96.

Hedge Funds Weigh In On Protara Therapeutics

Large investors have recently made changes to their positions in the business. Velan Capital Investment Management LP grew its position in Protara Therapeutics by 32.5% during the fourth quarter. Velan Capital Investment Management LP now owns 2,834,652 shares of the company’s stock valued at $15,109,000 after purchasing an additional 695,652 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Protara Therapeutics by 5.7% during the 3rd quarter. Vanguard Group Inc. now owns 1,904,156 shares of the company’s stock valued at $8,283,000 after buying an additional 102,176 shares during the period. Acorn Capital Advisors LLC grew its holdings in shares of Protara Therapeutics by 36.9% during the 2nd quarter. Acorn Capital Advisors LLC now owns 1,752,115 shares of the company’s stock valued at $5,309,000 after acquiring an additional 472,315 shares in the last quarter. UBS Group AG increased its stake in shares of Protara Therapeutics by 44.2% in the fourth quarter. UBS Group AG now owns 1,215,537 shares of the company’s stock worth $6,479,000 after acquiring an additional 372,463 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Protara Therapeutics by 7.7% in the fourth quarter. Geode Capital Management LLC now owns 817,196 shares of the company’s stock worth $4,357,000 after acquiring an additional 58,477 shares during the last quarter. Institutional investors and hedge funds own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.